US20230150913A1 - Synthesis of novel ketone body analogs for use as a nutritional supplement - Google Patents
Synthesis of novel ketone body analogs for use as a nutritional supplement Download PDFInfo
- Publication number
- US20230150913A1 US20230150913A1 US17/525,663 US202117525663A US2023150913A1 US 20230150913 A1 US20230150913 A1 US 20230150913A1 US 202117525663 A US202117525663 A US 202117525663A US 2023150913 A1 US2023150913 A1 US 2023150913A1
- Authority
- US
- United States
- Prior art keywords
- compounds
- hydroxy
- hydroxybutyl
- ketone bodies
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000002576 ketones Chemical class 0.000 title abstract description 25
- 235000015872 dietary supplement Nutrition 0.000 title abstract description 4
- 230000015572 biosynthetic process Effects 0.000 title description 19
- 238000003786 synthesis reaction Methods 0.000 title description 19
- 150000001875 compounds Chemical class 0.000 claims abstract description 59
- -1 β-Hydroxybutyl Chemical group 0.000 claims description 58
- 239000000203 mixture Substances 0.000 claims description 31
- UUFQTNFCRMXOAE-UHFFFAOYSA-N 1-methylmethylene Chemical compound C[CH] UUFQTNFCRMXOAE-UHFFFAOYSA-N 0.000 claims description 27
- 229910052739 hydrogen Inorganic materials 0.000 claims description 22
- 239000001257 hydrogen Substances 0.000 claims description 22
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 18
- 150000002148 esters Chemical class 0.000 claims description 17
- 125000002339 acetoacetyl group Chemical group O=C([*])C([H])([H])C(=O)C([H])([H])[H] 0.000 claims description 15
- 229920000642 polymer Polymers 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 4
- 150000002431 hydrogen Chemical group 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 238000000034 method Methods 0.000 abstract description 34
- 238000006243 chemical reaction Methods 0.000 abstract description 25
- XPFCZYUVICHKDS-UHFFFAOYSA-N 3-methylbutane-1,3-diol Chemical compound CC(C)(O)CCO XPFCZYUVICHKDS-UHFFFAOYSA-N 0.000 abstract description 24
- AXFYFNCPONWUHW-UHFFFAOYSA-N 3-hydroxyisovaleric acid Chemical compound CC(C)(O)CC(O)=O AXFYFNCPONWUHW-UHFFFAOYSA-N 0.000 abstract description 20
- 238000005809 transesterification reaction Methods 0.000 abstract description 11
- WDJHALXBUFZDSR-UHFFFAOYSA-M acetoacetate Chemical compound CC(=O)CC([O-])=O WDJHALXBUFZDSR-UHFFFAOYSA-M 0.000 abstract description 10
- 239000013589 supplement Substances 0.000 abstract description 10
- 230000036541 health Effects 0.000 abstract description 6
- 210000003205 muscle Anatomy 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 3
- 235000012631 food intake Nutrition 0.000 abstract description 3
- 230000037406 food intake Effects 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 208000033962 Fontaine progeroid syndrome Diseases 0.000 abstract description 2
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 abstract description 2
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 abstract 1
- 108010093096 Immobilized Enzymes Proteins 0.000 abstract 1
- 235000004251 balanced diet Nutrition 0.000 abstract 1
- 235000004280 healthy diet Nutrition 0.000 abstract 1
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 238000005160 1H NMR spectroscopy Methods 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000004576 sand Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 108090001060 Lipase Proteins 0.000 description 5
- 239000004367 Lipase Substances 0.000 description 5
- 102000004882 Lipase Human genes 0.000 description 5
- 239000010779 crude oil Substances 0.000 description 5
- 230000002255 enzymatic effect Effects 0.000 description 5
- 235000019421 lipase Nutrition 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- 108010084311 Novozyme 435 Proteins 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000006227 byproduct Substances 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- OMSUIQOIVADKIM-UHFFFAOYSA-N ethyl 3-hydroxybutyrate Chemical compound CCOC(=O)CC(C)O OMSUIQOIVADKIM-UHFFFAOYSA-N 0.000 description 4
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000012508 resin bead Substances 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- WRQNANDWMGAFTP-UHFFFAOYSA-N Methylacetoacetic acid Chemical compound COC(=O)CC(C)=O WRQNANDWMGAFTP-UHFFFAOYSA-N 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000003931 cognitive performance Effects 0.000 description 3
- 238000005886 esterification reaction Methods 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 229940040461 lipase Drugs 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 230000036314 physical performance Effects 0.000 description 3
- 238000012746 preparative thin layer chromatography Methods 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 150000003509 tertiary alcohols Chemical class 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- XFRBXZCBOYNMJP-UHFFFAOYSA-N 2,2,6-trimethyl-1,3-dioxin-4-one Chemical compound CC1=CC(=O)OC(C)(C)O1 XFRBXZCBOYNMJP-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 229920001429 chelating resin Polymers 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000011491 glass wool Substances 0.000 description 2
- 230000007407 health benefit Effects 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- JKUYRAMKJLMYLO-UHFFFAOYSA-N tert-butyl 3-oxobutanoate Chemical compound CC(=O)CC(=O)OC(C)(C)C JKUYRAMKJLMYLO-UHFFFAOYSA-N 0.000 description 2
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000222175 Diutina rugosa Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241001661345 Moesziomyces antarcticus Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108091007187 Reductases Proteins 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- WDJHALXBUFZDSR-UHFFFAOYSA-N acetoacetic acid Chemical group CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 description 1
- 150000004729 acetoacetic acid derivatives Chemical class 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 238000007171 acid catalysis Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000005815 base catalysis Methods 0.000 description 1
- GSCLMSFRWBPUSK-UHFFFAOYSA-N beta-Butyrolactone Chemical compound CC1CC(=O)O1 GSCLMSFRWBPUSK-UHFFFAOYSA-N 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 241001233037 catfish Species 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- WASQWSOJHCZDFK-UHFFFAOYSA-N diketene Chemical compound C=C1CC(=O)O1 WASQWSOJHCZDFK-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 235000006286 nutrient intake Nutrition 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- UQCWXKSHRQJGPH-UHFFFAOYSA-M tetrabutylazanium;fluoride;hydrate Chemical compound O.[F-].CCCC[N+](CCCC)(CCCC)CCCC UQCWXKSHRQJGPH-UHFFFAOYSA-M 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
- C07C69/12—Acetic acid esters
- C07C69/18—Acetic acid esters of trihydroxylic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
- C07C69/12—Acetic acid esters
- C07C69/21—Acetic acid esters of hydroxy compounds with more than three hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
- C07C69/675—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
- C07C69/716—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
- C07C69/72—Acetoacetic acid esters
Definitions
- the present invention relates to the synthesis of novel compounds, more specifically ketone body analogs for use as nutritional supplements.
- Ketone bodies are metabolites that the human body forms through the breakdown of fats during times of low food intake or other health related issues.
- Three major ketone bodies are acetoacetate, ⁇ -hydroxybutyrate, and acetone. Acetoacetate and ⁇ -hydroxybutyrate will be further metabolized to generate energy for the body, with acetone being a by-product Ketone bodies can be externally supplemented to achieve benefits without the breakdown of fats.
- Ketone body esters which are metabolically bioavailable versions of ketone bodies, have been shown in supplement form to encompass the beneficial aspects of ketone bodies.
- ⁇ -Hydroxy ⁇ -methylbutyrate is a molecule that is available from natural sources such as catfish, aged meats, grapefruit and corn, however, it is available only in small quantities. ⁇ -Hydroxy ⁇ -methylbutyrate is obtained through the catabolism of the amino acid leucine, but with a low yielding conversion rate.
- the use of ⁇ -hydroxy ⁇ -methylbutyrate as a supplement has shown to have health benefits including activation of the mTOR kinase, which initiates protein synthesis to help build and repair muscles.
- the supplementation of ⁇ -hydroxy ⁇ -methylbutyrate has also been shown to prevent protein degradation. Preventing muscle loss and promoting the repair and development of muscles is important, especially in a variety of the population including athletes and the aging.
- Both ketone bodies and ⁇ -hydroxy ⁇ -methylbutyrate are significant compounds that can help a vast number of individuals, suffering from reduced physical or cognitive performances.
- new and novel molecules which would incorporate the benefits of both ketone bodies and ⁇ -hydroxy ⁇ -methylbutyrate.
- the present invention provides the description of and a method to synthesize a novel and unique group of compounds that incorporate the beneficial properties found in ketone bodies such as acetoacetate and ⁇ -hydroxybutyrate in addition to the benefits seen with the supplementation of ⁇ -hydroxy ⁇ -methylbutyrate.
- the present invention provides a method of synthesis for a new group of compounds that incorporate the properties found in acetoacetate and ⁇ -hydroxybutyrate molecules with that of ⁇ -hydroxy ⁇ -methylbutyrate.
- transesterification Another aspect of the present invention relates to a reaction termed “transesterification.”
- the synthesis of the molecules of the present invention utilizes a reaction called transesterification.
- Transesterification is a chemical exchange of R-groups between an ester and an alcohol to form new esters and alcohols with the ester typically being the desired product as shown in the equation below:
- the desired ester can also be prepared via an esterification reaction, where a carboxylic acid is reacted with an alcohol to form the new ester with water as a by-product:
- the present invention provides a compound of formula (I)
- R 1 is selected from the group comprising of: (a) Hydrogen, wherein R 2 is not hydrogen, (b) Acetoacetyl (CH 3 COCH 2 CO—), (c) ⁇ -Hydroxybutyl (CH 3 CH(OH)CH 2 CO—), (d)(R)- ⁇ -Hydroxybutyl (CH 3 CH(OH)CH 2 CO—), (e) (S)- ⁇ -Hydroxybutyl (CH 3 CH(OH)CH 2 CO—); R 2 is selected from the group comprising of: (a) Hydrogen, wherein R 1 is not hydrogen, (b) Acetoacetyl (CH 3 COCH 2 CO—), (c) ⁇ -Hydroxybutyl (CH 3 CH(OH)CH 2 CO—), (d) (R)— ⁇ -Hydroxybutyl (CH 3 CH(OH)CH 2 CO—), (e) (S)- ⁇ -Hydroxybutyl (CH 3 CH(OH)CH 2 CO—);
- the compounds of formula (I) can be prepared via transesterification, esterification utilizing both enzymatic and nonenzymatic methods including microwave irradiation, sonication, photochemically, acid and base catalysis, soluble and supported enzymatic catalysis as well as other methods known to those skilled in the art.
- the present invention provides a route of synthesis for compounds of formula (I) using but not limited to using enzymatic methods including a lipase.
- immobilized enzymatic catalysts includes a vast number of lipases, but some of the most useful include the Porcine pancreatic lipase, lipase from Candida rugosa , and lipases from Candida antarctica.
- the present invention provides a route of synthesis for compounds of formula (I) using acidic catalysts such as but not limited to hydrochloric, phosphoric, sulfuric, sulfonic acids and basic catalysts such as but not limited to metal alkoxides, oxides, acetates, and amines, for example 4-dimethylaminopyridine and triethylamine.
- acidic catalysts such as but not limited to hydrochloric, phosphoric, sulfuric, sulfonic acids
- basic catalysts such as but not limited to metal alkoxides, oxides, acetates, and amines, for example 4-dimethylaminopyridine and triethylamine.
- Acetyl refers to the functionality with the formula CH 3 COCH 2 CO—
- ⁇ -Hydroxybutyl refers to the functionality with the formula CH 3 CH(OH)CH 2 CO—
- Esterification refers to the reaction of an alcohol with a carboxylic acid or a carboxylic acid derivative to give an ester.
- Transesterification refers to the chemical exchange of functionalities between an ester and an alcohol to form new esters and alcohols.
- esters is represented by the formula —OC(O)R, where R can be any organic group, typically an alkyl group.
- Derivative refers to a compound or portion of a compound that is derived from or is theoretically derivable from a parent compound.
- hydroxy is represented by the formula —OH.
- Polymer is a molecule that has repeating units called monomers, as used herein represents repeating units of acetoacetyl or p-hydroxybutyl functionalities.
- “Therapeutically acceptable” refers to those compounds (or salts, zwitterionic forms, esters, polymers, etc.) which are suitable for the treatment of diseases without undue toxicity, irritation, and allergic response, are commensurate with a reasonable benefit/risk ratio, and which are effective for their intended use.
- the present invention relates to a category of a transesterification reaction.
- the category of transesterification reactions can be divided into subtypes based on the compounds used within the transesterification.
- One of those subtyped reactions is called a transacetoacetylation and it is defined as a transesterification of a nucleophile with an acetoacetate group to form a new acetoacetate ester:
- Acetoacetate esters have several applications in industries including agrichemical and polymer industries, but their importance for the synthesis of ketoesters will be discussed.
- the present invention generates new molecules that would contain the properties of both ketone bodies and f-hydroxy ⁇ -methylbutyrate. These molecules may be prepared using transesterification methods by both enzymatic and nonenzymatic procedures.
- the source of ⁇ -hydroxy ⁇ -methylbutyrate must be addressed in the present invention. To combine ketone bodies with ⁇ -hydroxy ⁇ -methylbutyrate, a different starting molecule would be necessary as a source of ⁇ -hydroxy ⁇ -methylbutyrate.
- 3-methyl-1,3-butanediol also known as isopentyldiol
- a source of an acetoacetyl molecule such as, but not limited to, the acid or esters of acetoacetate including methyl acetoacetate, ethyl acetoacetate, tert-butyl acetoacetate, diketene, or 2,2,6-trimethyl-4H-1,3-dioxin-4-one.
- the reaction can be performed solventless or in various solvents, but not limited to ethyl acetate, toluene, xylene, or acetonitrile.
- the reaction is typically performed above room temperature and up to 150° C. While the preferred temperature for the reaction may be in the range of 20° C. to 150° C., it should be understood that reaction may take place above 150° C. and would likely provide for a faster reaction and reduce the byproducts of the reaction. However, this may occur at both lower and higher temperatures.
- the reactions may also be catalyzed with acids or bases such as sulfuric acid or triethylamine but are not limited to these compounds.
- the reaction can also be conducted with an enzyme, more specifically with a lipase in either the free form or immobilized on a solid support.
- the purification of these reactions to isolate the desired products may include column chromatography, distillation, extraction, and other more complex purification methods.
- the production of compounds of formula (I) that contain a ⁇ -hydroxybutyl (CH 3 CH(OH) CH 2 CO—) functionality can be formed from compounds with an acetoacetyl moiety utilizing a variety of reduction methods.
- the reduction can be performed using (but not limited to using) sodium borohydride or similar reducing agents in a protic solvent such as methanol and performing a reduction using a hydrogenating device including a Parr Shaker or a flow hydrogenator.
- a hydrogenating device including a Parr Shaker or a flow hydrogenator.
- the reduction can also be achieved via enzymatic methods using but not limited to reductases or alcohol dehydrogenases. These methods should consider the R/S enantiomers that would be generated. As each method may generate a specific enantiomer, the selection of reaction parameters including catalysts should be taken with care.
- This invention encompasses both racemic mixes and enantiomerically pure products.
- the compounds of formula (I) that contain a ⁇ -hydroxybutyl functionality can also be formed by reacting 3-methyl-1,3-butanediol, also known as isopentyldiol, with a source of the ⁇ -hydroxybutyl functionality.
- the source of 0-hydoxybutyl may be selected from the group ⁇ -hydroxybutyrate acid, esters of ⁇ -hydroxybutyrate such as ethyl-3-hydroxybutyrate, or ⁇ -Butyrolactone.
- ⁇ -hydroxybutyrates that may satisfy the requirements of the compounds to create formula (I).
- the starting reagents should be enantiomerically pure if the desired product is one of the enantiomers, if not a mix of enantiomers will be formed.
- a portion of 3-methyl-1,3-butanediol can be treated with the ⁇ -hydroxybutyl source under a variety of parameters as describe for the synthesis of the desired reduced compound.
- the desired compound of formula (I) is to have only an acetoacetyl or ⁇ -hydroxybutyl functionality on the tertiary alcohol of 3-methyl-1,3-butanediol a synthesis containing protecting groups is required.
- a protecting group such as but not limited to silyl ethers or acetyl groups can be used to protect the primary alcohol to allow for chemoselectivity of only the tertiary alcohol.
- the protecting group can be removed by a sufficient deprotection step typically using an acid or base.
- the first example formula is 3-hydroxy-3-methylbutyl 3-oxobutanoate:
- 3-hydroxy-3-methylbutyl 3-oxobutanoate There are various methods to synthesis 3-hydroxy-3-methylbutyl 3-oxobutanoate. As explained below, one method of the synthesis of 3-hydroxy-3-methylbutyl 3-oxobutanoate involves 3-methyl-1,3-butanediol (2.02 g, 19.44 mmol) and mixing it with ethyl acetoacetate (1.87 g, 14.34 mmol) and Novozym 435 resin beads (0.19 g, 10% w/w acyl donor). The mixture may be stirred at 65° C. in a sand bath for 24 hours with a glass capillary pierced through a septum for removal of the ethanol by-product while the preferred method is to stir the mixture at 65° C.
- the crude oil can then be dissolved in acetonitrile (5 mL) and 4 equivalents of propanal (4.51 g, 77.58 mmol) proportional to the original quantity of 3-methyl-1,3-butanediol were added.
- the mix is placed in an ice bath and stirred while adding Amberlyst® 15 hydrogen form dry (0.45 g. 10% w/w propanal) before capping for 30 minutes.
- the reaction should be monitored by TLC to determine when all the 3-methyl-1,3-butanediol is consumed. Once consumed, the reaction was concentrated down under vacuum to resulting in the desired compound as an oil.
- the resulting mixture can be run through filter paper to remove the white precipitate.
- the filtrate can be washed once with saturated NH 4 Cl solution (25 mL) and the organic layer dried with MgSO 4 , filtered, and evaporated down on a rotary evaporator.
- the resulting yellow liquid should be run through a 0.45 ⁇ m filter.
- To a 25 mL RBF was added the primary protected isopentyldiol (0.50 g, 2.27 mmol), 2,2,6-trimethyl-4H-1,3-dioxin-4-one (0.97 g, 6.82 mmol) and toluene (3 mL). The RBF was placed into a 140° C.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
- The present invention relates to the synthesis of novel compounds, more specifically ketone body analogs for use as nutritional supplements.
- Ketone bodies are metabolites that the human body forms through the breakdown of fats during times of low food intake or other health related issues. Three major ketone bodies are acetoacetate, β-hydroxybutyrate, and acetone. Acetoacetate and β-hydroxybutyrate will be further metabolized to generate energy for the body, with acetone being a by-product Ketone bodies can be externally supplemented to achieve benefits without the breakdown of fats. Besides the use of ketone bodies as an energy source there are more health benefits, such as helping with weight loss, aging, diabetes, Alzheimer's, Parkinson's, seizures, cancer, psychiatric disorders, and issues dealing with irregular glucose metabolism. Ketone body esters, which are metabolically bioavailable versions of ketone bodies, have been shown in supplement form to encompass the beneficial aspects of ketone bodies.
- β-Hydroxy β-methylbutyrate is a molecule that is available from natural sources such as catfish, aged meats, grapefruit and corn, however, it is available only in small quantities. β-Hydroxy β-methylbutyrate is obtained through the catabolism of the amino acid leucine, but with a low yielding conversion rate. The use of β-hydroxy β-methylbutyrate as a supplement has shown to have health benefits including activation of the mTOR kinase, which initiates protein synthesis to help build and repair muscles. The supplementation of β-hydroxy β-methylbutyrate has also been shown to prevent protein degradation. Preventing muscle loss and promoting the repair and development of muscles is important, especially in a variety of the population including athletes and the aging.
- As a result of poor dietary habits and an increasing aging population, there is an expanding market for nutritional supplements. There are a wide variety of supplements on the market used to reduce the effects of insufficient nutrient intake, due to an array of health conditions. Many health conditions are related to lowered food intake, which reduces both physical and cognitive performance. Ketone bodies and β-hydroxy β-methylbutyrate, separately have been used as supplements to address the reduced physical and cognitive performance. The combination of these molecules into a single supplemental compound could potentially lead to synergistic effects. A look into the background of the ketone bodies and β-hydroxy β-methylbutyrate are needed to understand their capabilities as supplements.
- Both ketone bodies and β-hydroxy β-methylbutyrate are significant compounds that can help a vast number of individuals, suffering from reduced physical or cognitive performances. There is a need for supplements that can combine the effects of both ketone bodies and β-hydroxy β-methylbutyrate. In summary, based on the above there is a need for new and novel molecules which would incorporate the benefits of both ketone bodies and β-hydroxy β-methylbutyrate.
- The present invention provides the description of and a method to synthesize a novel and unique group of compounds that incorporate the beneficial properties found in ketone bodies such as acetoacetate and β-hydroxybutyrate in addition to the benefits seen with the supplementation of β-hydroxy β-methylbutyrate.
- The present invention provides a method of synthesis for a new group of compounds that incorporate the properties found in acetoacetate and β-hydroxybutyrate molecules with that of β-hydroxy β-methylbutyrate.
- In this present embodiment, a novel group of molecules which combine the structures of acetoacetate and or β-hydroxybutyrate bonded to 3-methyl-1,3-butanediol, a proposed metabolic precursor to β-hydroxy β-methylbutyrate are disclosed. This embodiment will allow for a novel and improved source of ketone bodies and p-hydroxy β-methylbutyrate as an administration in a single supplement.
- Another aspect of the present invention relates to a reaction termed “transesterification.” The synthesis of the molecules of the present invention utilizes a reaction called transesterification. Transesterification is a chemical exchange of R-groups between an ester and an alcohol to form new esters and alcohols with the ester typically being the desired product as shown in the equation below:
-
RCOOR1+R2OH↔RCOOR2+R1OH - The desired ester can also be prepared via an esterification reaction, where a carboxylic acid is reacted with an alcohol to form the new ester with water as a by-product:
-
RCOOH+R1OH↔RCOOR1+H2O - In its principal embodiment, the present invention provides a compound of formula (I)
- R1 is selected from the group comprising of:
(a) Hydrogen, wherein R2 is not hydrogen,
(b) Acetoacetyl (CH3COCH2CO—),
(c) β-Hydroxybutyl (CH3CH(OH)CH2CO—),
(d)(R)-β-Hydroxybutyl (CH3CH(OH)CH2CO—),
(e) (S)-β-Hydroxybutyl (CH3CH(OH)CH2CO—);
R2 is selected from the group comprising of:
(a) Hydrogen, wherein R1 is not hydrogen,
(b) Acetoacetyl (CH3COCH2CO—),
(c) β-Hydroxybutyl (CH3CH(OH)CH2CO—),
(d) (R)—β-Hydroxybutyl (CH3CH(OH)CH2CO—),
(e) (S)-β-Hydroxybutyl (CH3CH(OH)CH2CO—);
or a therapeutically acceptable salt, ester, or polymer thereof. - Asymmetric centers exist in the compounds of the present invention and are designated by the letters “R” or “S,” depending on the configuration of substituents around the chiral carbon atom. It should be understood that the invention encompasses all stereochemical isomeric forms, both enantiomerically pure and any mixture thereof.
- The compounds of formula (I) can be prepared via transesterification, esterification utilizing both enzymatic and nonenzymatic methods including microwave irradiation, sonication, photochemically, acid and base catalysis, soluble and supported enzymatic catalysis as well as other methods known to those skilled in the art.
- In another embodiment the present invention provides a route of synthesis for compounds of formula (I) using but not limited to using enzymatic methods including a lipase. Examples of immobilized enzymatic catalysts includes a vast number of lipases, but some of the most useful include the Porcine pancreatic lipase, lipase from Candida rugosa, and lipases from Candida antarctica.
- In another embodiment the present invention provides a route of synthesis for compounds of formula (I) using acidic catalysts such as but not limited to hydrochloric, phosphoric, sulfuric, sulfonic acids and basic catalysts such as but not limited to metal alkoxides, oxides, acetates, and amines, for example 4-dimethylaminopyridine and triethylamine.
- The following explanations of terms and methods are provided to better describe the present disclosure and to guide those of ordinary skill in the art in the practice of the present disclosure.
- “Acetoacetyl” refers to the functionality with the formula CH3COCH2CO—
- “β-Hydroxybutyl” refers to the functionality with the formula CH3CH(OH)CH2CO—
- “Esterification” refers to the reaction of an alcohol with a carboxylic acid or a carboxylic acid derivative to give an ester.
- “Transesterification” refers to the chemical exchange of functionalities between an ester and an alcohol to form new esters and alcohols.
- The term “ester” is represented by the formula —OC(O)R, where R can be any organic group, typically an alkyl group.
- “Derivative” refers to a compound or portion of a compound that is derived from or is theoretically derivable from a parent compound.
- The term “hydroxy” is represented by the formula —OH.
- The term “oxo,” as used herein, represents=O.
- “Polymer” is a molecule that has repeating units called monomers, as used herein represents repeating units of acetoacetyl or p-hydroxybutyl functionalities.
- “Therapeutically acceptable” refers to those compounds (or salts, zwitterionic forms, esters, polymers, etc.) which are suitable for the treatment of diseases without undue toxicity, irritation, and allergic response, are commensurate with a reasonable benefit/risk ratio, and which are effective for their intended use.
- While the above definitions are used in this application to describe how one of ordinary skill in the art may generally understand the terms used to describe the invention, the definitions are not intended to limit the definition of the above terms in any manner. It is understood that the terms have much broader meaning than set forth above to those of skill in the art. The terms as used to describe the present invention are simply meant to provide a general understanding of when the terms may be used.
- Elements of the present invention may be better understood from the following description of the preferred embodiments. The preferred embodiments are intended to provide a description of the present invention and are not intended to limit the invention in any manner.
- The present invention relates to a category of a transesterification reaction. The category of transesterification reactions can be divided into subtypes based on the compounds used within the transesterification. One of those subtyped reactions is called a transacetoacetylation and it is defined as a transesterification of a nucleophile with an acetoacetate group to form a new acetoacetate ester:
- Acetoacetate esters have several applications in industries including agrichemical and polymer industries, but their importance for the synthesis of ketoesters will be discussed.
- Compounds of the present invention comprise of the ketone bodies acetoacetate and β-hydroxybutyrate being bonded to a 3-methyl-1,3-butanediol molecule of the formula (I). Representative list of compounds in this invention of formula (I):
- 3-hydroxy-3-methylbutyl 3-oxobutanoate
- 3-hydroxy-3-methylbutyl 3-hydroxybutanoate
- 4-hydroxy-2-methylbutan-2-yl 3-oxobutanoate
- 4-hydroxy-2-methylbutan-2-yl 3-hydroxybutanoate
- 2-methyl-4-[(3-oxobutanoyl)oxy]butan-2-yl 3-oxobutanoate
- 4-[(3-hydroxybutanoyl)oxy]-2-methylbutan-2-yl 3-oxobutanoate
- 3-[(3-hydroxybutanoyl)oxy]-3-methylbutyl 3-oxobutanoate
- 4-[(3-hydroxybutanoyl)oxy]-2-methylbutan-2-yl 3-hydroxybutanoate
- Asymmetric centers exist in the compounds of the present invention and are designated by the letters “R” or “S,” depending on the configuration of substituents around the chiral carbon atom. It should be understood that the invention encompasses all stereochemical isomeric forms, both enantiomerically pure and any mixture thereof. The invention also includes all therapeutically acceptable salts, esters, or polymers thereof.
- The present invention generates new molecules that would contain the properties of both ketone bodies and f-hydroxy β-methylbutyrate. These molecules may be prepared using transesterification methods by both enzymatic and nonenzymatic procedures. The source of β-hydroxy β-methylbutyrate must be addressed in the present invention. To combine ketone bodies with β-hydroxy β-methylbutyrate, a different starting molecule would be necessary as a source of β-hydroxy β-methylbutyrate.
- The production of compounds of formula(I) that contain an acetoacetyl (CHL3COCH2CO—)functionality are formed in both enzymatic and nonenzymatic routes of synthesis. 3-methyl-1,3-butanediol, also known as isopentyldiol, can be treated with a source of an acetoacetyl molecule such as, but not limited to, the acid or esters of acetoacetate including methyl acetoacetate, ethyl acetoacetate, tert-butyl acetoacetate, diketene, or 2,2,6-trimethyl-4H-1,3-dioxin-4-one. There does not currently exist a molecule that contains both the functionality of the group of the acid or esters of acetoacetate described above with the base formulation of formula (I). The reaction can be performed solventless or in various solvents, but not limited to ethyl acetate, toluene, xylene, or acetonitrile. The reaction is typically performed above room temperature and up to 150° C. While the preferred temperature for the reaction may be in the range of 20° C. to 150° C., it should be understood that reaction may take place above 150° C. and would likely provide for a faster reaction and reduce the byproducts of the reaction. However, this may occur at both lower and higher temperatures. The reactions may also be catalyzed with acids or bases such as sulfuric acid or triethylamine but are not limited to these compounds. The reaction can also be conducted with an enzyme, more specifically with a lipase in either the free form or immobilized on a solid support. The purification of these reactions to isolate the desired products may include column chromatography, distillation, extraction, and other more complex purification methods.
- The production of compounds of formula (I) that contain a β-hydroxybutyl (CH3CH(OH) CH2CO—) functionality can be formed from compounds with an acetoacetyl moiety utilizing a variety of reduction methods. The reduction can be performed using (but not limited to using) sodium borohydride or similar reducing agents in a protic solvent such as methanol and performing a reduction using a hydrogenating device including a Parr Shaker or a flow hydrogenator. There exist other methods that the reduction may be performed. For example, the reduction can also be achieved via enzymatic methods using but not limited to reductases or alcohol dehydrogenases. These methods should consider the R/S enantiomers that would be generated. As each method may generate a specific enantiomer, the selection of reaction parameters including catalysts should be taken with care. This invention encompasses both racemic mixes and enantiomerically pure products.
- The compounds of formula (I) that contain a β-hydroxybutyl functionality can also be formed by reacting 3-methyl-1,3-butanediol, also known as isopentyldiol, with a source of the β-hydroxybutyl functionality. The source of 0-hydoxybutyl may be selected from the group β-hydroxybutyrate acid, esters of β-hydroxybutyrate such as ethyl-3-hydroxybutyrate, or β-Butyrolactone. There are other β-hydroxybutyrates that may satisfy the requirements of the compounds to create formula (I). The starting reagents should be enantiomerically pure if the desired product is one of the enantiomers, if not a mix of enantiomers will be formed. A portion of 3-methyl-1,3-butanediol can be treated with the β-hydroxybutyl source under a variety of parameters as describe for the synthesis of the desired reduced compound.
- If the desired compound of formula (I) is to have only an acetoacetyl or β-hydroxybutyl functionality on the tertiary alcohol of 3-methyl-1,3-butanediol a synthesis containing protecting groups is required. A protecting group such as but not limited to silyl ethers or acetyl groups can be used to protect the primary alcohol to allow for chemoselectivity of only the tertiary alcohol. After the ketone body functionality has been attached to the tertiary alcohol, the protecting group can be removed by a sufficient deprotection step typically using an acid or base.
- The present invention will now be described in connection with certain preferred embodiments which are not intended to limit its scope. On the contrary, the present invention covers all alternatives, modifications, and equivalents as can be included within the scope of the claims. The following examples, which include preferred embodiments, will illustrate the preferred practice of the present invention, it being understood that the examples are for the purposes of illustration of certain preferred embodiments and are presented to provide what is believed to be the most useful and readily understood description of its procedures and conceptual aspects.
- The first example formula is 3-hydroxy-3-methylbutyl 3-oxobutanoate:
- There are various methods to synthesis 3-hydroxy-3-methylbutyl 3-oxobutanoate. As explained below, one method of the synthesis of 3-hydroxy-3-methylbutyl 3-oxobutanoate involves 3-methyl-1,3-butanediol (2.02 g, 19.44 mmol) and mixing it with ethyl acetoacetate (1.87 g, 14.34 mmol) and Novozym 435 resin beads (0.19 g, 10% w/w acyl donor). The mixture may be stirred at 65° C. in a sand bath for 24 hours with a glass capillary pierced through a septum for removal of the ethanol by-product while the preferred method is to stir the mixture at 65° C. in a sand bath for 24 hours, those of ordinary skill in the art would understand that the mixture could be stirred using other methods at a variety of temperatures. Periodic TLC testing showed the consumption of the ethyl acetoacetate after 24 hours with unreacted 3-methyl-1,3-butanediol. To the mixture diethyl ether (5 mL) may be added to dissolve the mixture and then ran through a filter to separate off the beads. In a preferred method of filtering utilities, a plug of glass wool, but any known filtering system to separate the beads maybe used. The reaction mixture can be concentrated under vacuum. The crude oil can then be dissolved in acetonitrile (5 mL) and 4 equivalents of propanal (4.51 g, 77.58 mmol) proportional to the original quantity of 3-methyl-1,3-butanediol were added. The mix is placed in an ice bath and stirred while adding Amberlyst® 15 hydrogen form dry (0.45 g. 10% w/w propanal) before capping for 30 minutes. The reaction should be monitored by TLC to determine when all the 3-methyl-1,3-butanediol is consumed. Once consumed, the reaction was concentrated down under vacuum to resulting in the desired compound as an oil. MS m/c 173 [M—CH3]; 1H NMR (CDCl3): δ 12.03 (s, 1H), δ 4.98 (s, 2H), β 4.49 (t, 2H), δ 3.47 (s, 2H), δ 2.27 (s, 3H), δ 1.96 (s, 3H), δ 1.78 (t, 2H), δ 1.27 (s, 6H); IR (neat) 3423, 2972, 2935, 1735, 1708, 1147 cm−1.
- The second example formula is set forth for 3-hydroxy-3-methylbutyl 3-oxobutanoate:
- There are various methods to synthesis 3-hydroxy-3-methylbutyl 3-oxobutanoate. An explanation of how the formula was derived is described below. First 3-methyl-1,3-butanediol (1.01 g, 9.70 mmol) is mixed with methyl acetoacetate (1.61 g, 13.87 mmol) and Novozym 435 resin beads (0.14 g, 8.4% w/w acyl donor). The mixture can be stirred at 60° C. for 24 hours. While the preferred method calls for stirring the mixture at 60° C. for 24 hours, other methods of stirring may be utilized. The reaction mixture may be concentrated under vacuum. The crude oil may then be purified on silica gel with Heptane: EtOAc 1:1 resulting in the desired compound as an oil. MS; 1H NMR; IR: See Example 1.
- The third example formula is set forth below for 3-hydroxy-3-methylbutyl 3-oxobutanoate:
- There are various methods to synthesis 3-hydroxy-3-methylbutyl 3-oxobutanoate. An explanation of how the formula was derived is described as follows. First, 3-methyl-1,3-butanediol (0.98 g, 9.41 mmol) is mixed with methyl acetoacetate (1.63 g, 14.04 mmol) and a catalytic amount of triethylamine (40 μL) was added. The reaction was heated at 100° C. for 24 hours. While the preferred method calls for heating the reaction to 100° C., it should be understood that higher temperatures may be utilized without departing from the nature of the invention. The reaction mixture can then be concentrated under vacuum. The crude oil is then purified on silica gel with Heptane: EtOAc 1:1 resulting in the desired compound as an oil. MS; 1H NMR; IR: See Example 1.
- The fourth example formula is set forth below for 3-hydroxy-3-methylbutyl 3-oxobutanoate:
- There are various methods to synthesis 3-hydroxy-3-methylbutyl 3-oxobutanoate. An explanation of how the formula was derived is described as follows. First, 3-methyl-1,3-butanediol (0.49 g, 4.74 mmol) was mixed with tert-butyl acetoacetate (1.01 g, 6.38 mmol) were vigorously stirred at 100° C. for 12 hours. The resulting mixture was concentrated under vacuum. The crude oil was then dissolved in acetonitrile (5 mL) and 4 equivalents of propanal (0.82 g, 14.11 mmol) to starting 3-methyl-1,3-butanediol were added. The mix was placed in an ice bath and stirred while adding Amberlyst® 15 hydrogen form dry (0.08 g, 10% w/w propanal) before capping for 30 minutes. The reaction was monitored by TLC to determine when all the 3-methyl-1,3-butanediol was consumed. Once consumed, the reaction was concentrated down under vacuum to resulting in the desired compound as an oil. MS; 1H NMR; IR: See Example 1.
- The fifth example formula is set forth below for 3-hydroxy-3-methylbutyl 3-hydroxybutanoate:
- There are various methods to synthesis 3-hydroxy-3-methylbutyl 3-hydroxybutanoate. An explanation of how the formula was derived is described as follows. First, 3-methyl-1,3-butanediol (1.00 g, 9.64 mmol) was mixed with ethyl-3-hydroxybutyrate (0.63 g, 4.78 mmol), and Novozym 435 resin beads (0.06 g, 10% w/w acyl donor). The mixture was stirred vigorously in a 55° C. sand bath for 12 hours. While the preferred stirring method was set out above, it should be understood that other vigorous stirring methods at various temperatures without departing from the nature of the invention. The product was purified by preparative TLC. MS m/e 175 [M-CH3]; 1H NMR: δ 4.32 (t, 2H), δ 2.53 (q, 1H), δ 2.39 (d, 2H), δ 1.86 (t, 2H), δ 1.28 (s, 6H), δ 1.17 (d, 3H); IR: 3385, 2970, 2929, 1714, 1170, 1070 cm−1.
- The sixth example formula is set forth below for 3-hydroxy-3-methylbutyl 3-hydroxybutanoate:
- There are various methods to synthesis 3-hydroxy-3-methylbutyl 3-hydroxybutanoate. An explanation of how the formula was derived is described as follows. First, 3-methyl-1,3-butanediol (3.03 g, 29.11 mmol), ethyl acetoacetate (4.12 g, 31.67 mmol) and Novozym 435 (0.35 g, 8.5% w/w acyl donor) were mixed together. The mixture may be placed into an 80° C. sand bath and stirred vigorously overnight. While the preferred method calls for heating the reaction to 100° C., it should be understood that higher temperatures may be utilized without departing from the nature of the invention. After 18 hours the mixture was removed from the heat and the mixture was diluted with diethyl ether (10 mL) and filtered through a glass wool plug to remove the beads. Then a portion of the reaction mixture (1.00 g, 5.32 mmol) and sodium borohydride (0.16 g, 4.34 mmol) was dissolved in isopropanol (6 mL). The mixture is placed in an ice bath and stirred for 12 hours and allowed to reach room temperature. The mixture may be concentrated under vacuum and then diluted with dichloromethane (20 mL). The mixture may be washed two times with brine (10 mL) and then the organic layer is separated and dried with MgSO4. The organic layer can be concentrated under vacuum resulting in a crude oil of the desired compound, which was further purified by preparative TLC. MS; 1H NMR; IR: See Example 5.
- The seventh example formula is set forth below for 2-methyl-4-[(3-oxobutanoyl)oxy]butan-2-yl 3-oxobutanoate:
- There are various methods to synthesis 2-methyl-4-[(3-oxobutanoyl)oxy]butan-2-yl 3-oxobutanoate. An explanation of how the formula was derived is described as follows. First, to a solution of 3-methyl-1,3-butanediol (0.53 g, 5.09 mmol) and toluene (5 mL) was added 2,2,6-trimethyl-4H-1,3-dioxin-one (1.56 g, 10.94 mmol). The mixture may be stirred vigorously for 30 minutes in a 140° C. sand bath. While the preferred method calls for heating the reaction to 100° C., it should be understood that higher temperatures may be utilized without departing from the nature of the invention. Then to the mixture can be added diethyl ether (5 mL) and the mixture was filtered to remove the resin beads. The solution was concentrated under vacuum. The crude mix was analyzed to confirm the purity and identity of the desired product. 1H NMR: δ 11.98 (s, 1H), δ 4.74 (t, 2H), δ 4.25 (t, 2H), δ 3.42 (s, 2H), δ 2.26 (s, 6H), δ 1.74 (t, 2H), δ 1.25 (t, 6H); IR: 2976, 2937, 1732, 1712, 1645 cm−1.
- The eighth example formula is set forth below for 4-hydroxy-2-methylbutan-2-yl 3-oxobutanoate:
- There are various methods to synthesis 4-hydroxy-2-methylbutan-2-yl 3-oxobutanoate. An explanation of how the formula was derived is described as follows. First, 3-methyl-1,3-butanediol (5.04 g, 48.44 mmol), Imidazole (3.60 g, 52.83 mmol), tert-Butyldimethylsilyl chloride (7.96 g, 52.81 mmol) and dichloromethane (70 mL) should be added together. The mixture can be capped and stirred vigorously in an ice bath for 5 hours. While the preferred method calls for heating the reaction to 100° C., it should be understood that higher temperatures may be utilized without departing from the nature of the invention. Then the resulting mixture can be run through filter paper to remove the white precipitate. The filtrate can be washed once with saturated NH4Cl solution (25 mL) and the organic layer dried with MgSO4, filtered, and evaporated down on a rotary evaporator. The resulting yellow liquid should be run through a 0.45 μm filter. To a 25 mL RBF was added the primary protected isopentyldiol (0.50 g, 2.27 mmol), 2,2,6-trimethyl-4H-1,3-dioxin-4-one (0.97 g, 6.82 mmol) and toluene (3 mL). The RBF was placed into a 140° C. sand bath with a reflux column and stirred vigorously for 45 minutes. To a 5 ml vial was added (0.10 g, 0.45 mmol), tetrabutylammonium fluoride hydrate (0.25 g, 0.80 mmol) and 2 mL THF. The vial was capped and stirred vigorously for 13 hours. Purification was performed with preparative TLC and analyzed by GCMS. MS m/e 173 [M-CH3].
- It will be evident to one skilled in the art that the present invention is not limited to the foregoing illustrative examples, and that it can be embodied in other specific forms without departing from the essential attributes thereof. It is therefore desired that the examples be considered in all respects as illustrative and not restrictive, reference being made to the appended claims, rather than to the foregoing examples, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.
- While specific combinations of compounds are disclosed in specific embodiments, it should be understood that there exist numerous combinations of the different compound which may be utilized in the compound of the formulas for the present invention.
- The foregoing disclosure and description of the invention are illustrative and explanatory thereof, and various changes in the compounds of illustrated formulas may be changed without departing from the spirit of the invention.
- It is understood that the invention is not limited to the specific embodiments disclosed and that modifications and other embodiments are intended to be included within the scope of the appended claims. Although specific terms are employed herein, they are used in a generic and descriptive sense only and not for purposes of limitation.
Claims (20)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/525,663 US11807600B2 (en) | 2021-11-12 | 2021-11-12 | Synthesis of novel ketone body analogs for use as a nutritional supplement |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/525,663 US11807600B2 (en) | 2021-11-12 | 2021-11-12 | Synthesis of novel ketone body analogs for use as a nutritional supplement |
Publications (2)
Publication Number | Publication Date |
---|---|
US20230150913A1 true US20230150913A1 (en) | 2023-05-18 |
US11807600B2 US11807600B2 (en) | 2023-11-07 |
Family
ID=86325178
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/525,663 Active 2042-04-02 US11807600B2 (en) | 2021-11-12 | 2021-11-12 | Synthesis of novel ketone body analogs for use as a nutritional supplement |
Country Status (1)
Country | Link |
---|---|
US (1) | US11807600B2 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5349026A (en) * | 1992-11-20 | 1994-09-20 | Rohm And Haas Company | Reactive coalescents |
WO2023283654A1 (en) * | 2021-07-09 | 2023-01-12 | Georgia State University Research Foundation, Inc. | The use of beta-hydroxybutyrates for the treatment or prevention of aneurysms and dissections |
WO2023054702A1 (en) * | 2021-09-30 | 2023-04-06 | クミアイ化学工業株式会社 | Aldehyde compound production method and dihydroisoxazole compound production method |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6323237B1 (en) | 1997-03-17 | 2001-11-27 | Btg International Limited | Therapeutic compositions |
US6812249B2 (en) | 2003-03-04 | 2004-11-02 | Sal Abraham | Process for preparing a 3-hydroxy-3-methylbutyrate amino acid salt and method of use |
US8642654B2 (en) | 2009-04-16 | 2014-02-04 | Isis Innovation Limited | Hydroxybutyrate ester and medical use thereof |
AU2009344282B2 (en) | 2009-04-16 | 2014-12-11 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Process for the preparation of (3R)-hydroxybutyl (3R)-hydroxybutyrate by enzymatic enantioselective reduction employing Lactobacillus brevis alcohol dehydrogenase |
GB201002983D0 (en) | 2010-02-22 | 2010-04-07 | Tdeltas Ltd | Nutritinal composition |
GB201206192D0 (en) | 2012-04-05 | 2012-05-23 | Tdeltas Ltd | Ketone bodies and ketone body esters and for maintaining or improving muscle power output |
US20160184248A1 (en) | 2014-12-15 | 2016-06-30 | University Of Central Florida Research Foundation Inc. | Compositions and methods of use of -hydroxy-methylbutyrate (hmb) resulting in an acute endocrine response |
US10245243B1 (en) | 2017-12-19 | 2019-04-02 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use |
US20180057846A1 (en) | 2016-08-30 | 2018-03-01 | KetoneAid Inc. | Partially buffered free acid and/or ketone blend for rapid onset ketosis and metabolic therapy |
US20180055797A1 (en) | 2016-08-31 | 2018-03-01 | KetoneAid Inc. | Non-racemic ketone salts for rapid-onset nutritional ketosis and metabolic therapy |
US20190119705A1 (en) | 2017-10-20 | 2019-04-25 | KetoneAid Inc. | Substantially non-racemic ketone ester of beta hydroxybutyrate and production process thereof |
US10925843B2 (en) | 2018-04-18 | 2021-02-23 | Axcess Global Sciences, Llc | Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate |
-
2021
- 2021-11-12 US US17/525,663 patent/US11807600B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5349026A (en) * | 1992-11-20 | 1994-09-20 | Rohm And Haas Company | Reactive coalescents |
WO2023283654A1 (en) * | 2021-07-09 | 2023-01-12 | Georgia State University Research Foundation, Inc. | The use of beta-hydroxybutyrates for the treatment or prevention of aneurysms and dissections |
WO2023054702A1 (en) * | 2021-09-30 | 2023-04-06 | クミアイ化学工業株式会社 | Aldehyde compound production method and dihydroisoxazole compound production method |
Also Published As
Publication number | Publication date |
---|---|
US11807600B2 (en) | 2023-11-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230295672A1 (en) | Process for producing (r)-3-hydroxybutyl (r)-3-hydroxybutyrate | |
Orrenius et al. | Candida antarctica lipase B catalysed kinetic resolutions: Substrate structure requirements for the preparation of enantiomerically enriched secondary alcanols | |
Shimojo et al. | Enzyme-mediated preparation of optically active 1, 2-diols bearing a long chain: Enantioselective hydrolysis of cyclic carbonates | |
US20110245338A1 (en) | Chiral intermediate, process for producing the same and its use in the manufacture of tolterodine, fesoterodine, or the active metabolite thereof | |
KR101451171B1 (en) | Manufacturing method of (Loxoprofen (2S, 1'R, 2'S) trans-alcohol | |
WO2007139238A1 (en) | Process for l-carnitine and acetyl l-carnitine hydrochloride | |
JP4015450B2 (en) | Method for producing optically active alcohol | |
JPH05331128A (en) | @(3754/24)r)-@(3754/24)-)-4-cyano-3-hydroxylactic acid t-butyl ester and its production | |
CN104450811A (en) | Process for preparing a carbamate compound | |
US11807600B2 (en) | Synthesis of novel ketone body analogs for use as a nutritional supplement | |
JP2011068587A (en) | New aminoalcohol derivative salt, asymmetric organic molecule catalyst having aminoalcohol derivative salt structure and method for producing optically active compound with the asymmetric organic molecule catalyst | |
JPH1057094A (en) | Enzymatic optical resolution of alcohol using ketene acetal type acylating agent | |
EP2218788B1 (en) | Process for the preparation of optically active cyclopentenones | |
KR20070095618A (en) | Process for l-carnitine | |
JP3049403B2 (en) | Optically active trans-2-aryl-1-cyclohexanol derivative and method for producing the same | |
Marhold et al. | Synthesis of optically active 2-fluoroalk-1-en-3-yl esters and chirality transfer in their Claisen-type rearrangements | |
JP2846770B2 (en) | Optical resolution method for obtaining optically active trans-2-aminocyclohexanol derivative | |
JP2022536492A (en) | A process for preparing polyol-based esters of hydroxycarboxylic acids, especially polyglycerol esters. | |
JP5780651B2 (en) | Asymmetric synthesis of equol | |
JP2594605B2 (en) | Optically active α, α-difluoro-β-hydroxycarbonyl compound | |
EP1833977B1 (en) | Enantioconvergent chemoenzymatic synthesis of (r)- gamma-amino-beta-hydroxybutyric acid ((r) - gabob) | |
JPH05501883A (en) | Protected Hydroxy Method for Alcohol-Ester Separation | |
JPH0791223B2 (en) | Process for producing optically active 6-t-butoxy-3,5-dihydroxyhexanoic acid ester | |
KR100832749B1 (en) | Method for preparing chiral alpha fluoromethyl propargyl alcohol derivatives | |
JP4789889B2 (en) | Method for producing (R) -2-alkylcyclopentanone |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: MICROENTITY |
|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: MICROENTITY |
|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO MICRO (ORIGINAL EVENT CODE: MICR); ENTITY STATUS OF PATENT OWNER: MICROENTITY |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |